MMP1 and prostate carcinoma: No significant association between MMP-1-1607 1G/2G polymorphism and risk of prostate cancer was observed in the overall analyses (2G vs. 1G: OR = 0.69, 95% CI = 0.40–1.19; 2G/2G vs. 1G/1G: OR = 0.61, 95% CI = 0.25–1.46; 1G/2G vs. 1G/1G: OR = 1.07, 95% CI = 0.69–1.66; 2G/2G vs. 1G/1G+1G/2G: OR = 0.58, 95% CI = 0.27–1.22; 2G/2G+1G/2G vs. 1G/1G: OR = 0.84, 95% CI = 0.57–1.24).